Zogenix, Inc.: Series B $20M

Posted in I - Series B, Q - 4Q09, R - WEST, X - Device (Delivery), X - Drug:Device Combo, XX - CA

Zogenix (San Diego, CA) a clinical-stage drug:device company focused on a needle-free delivery system of chronic pain therapeutics, closed a $20M Series B financing, bringing the total round to $71M. Participants have included Chicago Growth Partners, Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas McNerney & Partners, Oxford Finance and Abingworth Management.
Note: 2009 Year-in-Review Trend [...]

Feb

2010

Apnex Medical, Inc.: Series B $14M

Posted in I - Series B, Q - 4Q09, R - MID WEST, X - Device (Sleep Apnea), XX - MN

Apnex Medical (St. Paul, MN) a clinical-stage medical device company developing an implantable treatment for moderate-to-severe obstructive sleep apnea, closed a $14M Series B financing. Participants include Domain Associates, New Enterprise Associates and Polaris Venture Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Feb

2010

Afferent Pharmaceuticals, Inc.: Series A $23M

Posted in I - Series A, Q - 4Q09, R - WEST, X - Pain, XX - CA

Afferent Pharmaceuticals (Palo Alto, CA) a clinical-stage biopharmaceutical company focused on pain associated with conditions such as osteoarthritis, back pain, visceral pain and neuropathy, closed a $23M Series A financing. Participants include Third Rock Ventures, Pappas Ventures, Domain Associates and New Leaf Venture Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Feb

2010

Regado Biosciences, Inc.: Series D $40M

Posted in I - Series D, Q - 4Q09, R - NORTH EAST, X - Anticoagulant, X - Aptamer, XX - NJ

Regado Biosciences (Basking Ridge, NJ) a clinical-stage biopharmaceutical company with an aptamer platform drug-antidote pairing system focused upon the anticoagulant market, closed a $40M Series D financing. Participants include Edmond de Rothschild Investment Partners, Domain Associates, Quaker Bioventures, Aurora Funds and Caxton Advantage Life Sciences Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Feb

2010

Altair Therapeutics, Inc.: Series B $17M

Posted in I - Series B, Q - 4Q09, R - WEST, X - Asthma, X - Respiratory, X - Rhinitis, XX - CA

Altair Therapeutics (San Diego, CA) a clinical-stage biopharmaceutical company focused on antisense therapeutics for asthma and rhinitis, closed a $17M Series B financing. Participants include Domain Associates, AgeChem Venture Fund, Thomas McNerney & Partners and Forward Ventures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Oct

2009

Zogenix, Inc.: Series B $36M

Posted in I - Series B, Q - 3Q09, R - WEST, X - Device (Delivery), X - Drug:Device Combo, X - Pain, XX - CA

Zogenix (San Diego, CA) a clinical-stage drug:device company focused on a needle-free delivery system of chronic pain therapeutic, closed a $51M Series B financing. Participants include Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partners, Oxford Finance and Abingworth Management.

Next Entries »

to top of page...